moomoo ID:NaN
Log Out
Log in to access Online Inquiry

ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Passes Above 50 Day Moving Average of $3.78

Defense World ·  {{timeTz}}

Shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $3.78 and traded as high as $4.00. ZIVO Bioscience shares last traded at $3.88, with a volume of 4,607 shares.

ZIVO Bioscience Trading Down 1.0 %

The business's fifty day moving average is $3.78 and its 200 day moving average is $3.59.

Get ZIVO Bioscience alerts:

ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last announced its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On ZIVO Bioscience

An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. boosted its holdings in shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 92,468 shares of the biotechnology company's stock after acquiring an additional 15,147 shares during the period. Vanguard Group Inc. owned about 0.98% of ZIVO Bioscience worth $359,000 at the end of the most recent reporting period. 5.54% of the stock is owned by hedge funds and other institutional investors.

ZIVO Bioscience Company Profile

(Get Rating)

ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.

Featured Stories

  • Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
  • Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
  • Is PayPal A Buy After Post-Earnings Price Jump?
  • Williams-Sonoma's High-End Consumers Are Still Spending
  • Snowflake Stock Soars On Strong Results
  • ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?

Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.